RecruitingNCT06814444

Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

170 participants

Start Date

Nov 11, 2023

Study Type

OBSERVATIONAL

Conditions

Acute Leukemia

Summary

LThe main aim of this project is to provide an immunophenotypic and immunometabolic characterisation of patients with Acute Leukaemia, before and after therapy, and to understand how changes in the immune system impact the response to therapy. Specifically: 1. The association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system will be assessed, in order to identify immune-modulatory metabolic mechanisms activated by malignant cells. 2. The association between immunometabolic signatures and response to therapies will be assessed. 3. The role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells will be explored.

Eligibility

Min Age: 18 Years

Inclusion Criteria8

PATIENT
Diagnosis of Acute Leukaemia.
Eligibility for a treatment scheme involving either conventional chemotherapy or innovative therapies, such as monoclonal antibodies, molecular therapies with specific targets, metabolic and immunological therapies.
age ≥ 18 years.
Signature of informed consent by patients at the time of diagnosis.
Healthy donors (AIL BOLOGNA ODV volunteers)
age ≥ 18 years.
Signature of informed consent.